Hematologic Malignancies Therapeutics Market [By Type (Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia), Lymphoma, Multiple Myeloma, and Others); By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others); and By Regions (North America - U.S., Canada; Europe - Germany, UK, France, Italy; Asia-Pacific - China, India, Japan, Australia; Latin America - Brazil, Mexico; Middle East & Africa)]: Market size & Forecast, 2018 - 2025

Choose License

The Global Hematologic Malignancies Therapeutics Market Size is anticipated to reach over USD 87.0 Billion by 2025 according to a new research. 
 
Hematological malignancy is a type of cancer that affect the bone marrow, blood, and lymph nodes. They include several forms of myeloma, leukemia, and lymphoma. According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias. Excluding Hodgkin's lymphoma as well as acute lymphocytic leukemia, these types of malignancy are usually related to growing age. Hence, considering the aging worldwide population, malignancy type is more probable to become more prevalent.
 
The global Hematologic Malignancies Therapeutics Market growth is majorly driven by the increasing focus on development for novel treatments and growing occurrence of blood cancer. Currently, blood malignancies are the second most leading cause of cancer deaths and the 5th most common cancer. The three most common types of blood cancers are multiple myeloma leukemia, and lymphoma. Each year, approximately 400,000 people are diagnosed with lymphoma and more than 300,000 people are diagnosed with leukemia globally. In addition, inventions of novel drugs for blood cancer and its regulatory approvals are anticipated to bolster the market growth. For instance, in 2015, Pfizer announced that its antibody-drug conjugate- inotuzumab has received USFDA approval for acute lymphoblastic leukemia.  
 
The Global Hematologic Malignancies Therapeutics Market is segmented on the basis of type, therapy, and geography. Based on type, the market is segmented into leukemia, lymphoma, multiple myeloma, and others. The leukemia is further segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. On the basis of type, leukemia was estimated to dominate the market. The major market share is due to availability of products such as Imbruvica, Rituxan, and Glivec, which are estimated to be the highest revenue generating drugs. On the basis of therapy, the global Hematologic Malignancies Therapeutics Market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Amongst all the therapies, chemotherapy is the most commonly used treatment with a particular drug or combination of drugs used.
 
On the basis of region, the global Hematologic Malignancies Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was estimated to dominate the global market. The dominance is majorly attributed to the high presence of key market players, availability of branded drugs, established healthcare organization, and increasing government support in the region. However, Asia Pacific is expected to dominate the global market during the forecast period. Increasing awareness about early diagnosis, availability of effective treatment in emerging countries, such as India and China, growing healthcare expenditure, and high unmet clinical needs of patients, are some of the factors anticipated to significantly boost the market in the Asia Pacific.
 
Some major key players in global Hematologic Malignancies Therapeutics Market includes Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company limited among others. The object of the key market players is to deliver better chronic care administration while keeping the cost low. In addition, the companies are concentrating on producing easy-to-use monitoring devices that can aid patients to accomplish conditions including diabetes or heart diseases better by avoiding costly medical processes.
Table of Contents
1.	Overview and Scope
1.1.	Research goal & scope
1.2.	Research assumptions
1.3.	Research Methodology
1.3.1.	Primary data sources
1.3.2.	Secondary data sources
1.4.	Key take-aways
1.5.	Stakeholders
2.	Executive Summary
2.1.	Market Definition
2.2.	Market Segmentation
3.	Hematologic Malignancies Therapeutics Market Insights
3.1.	Hematologic Malignancies Therapeutics? Industry snapshot
3.2.	Hematologic Malignancies Therapeutics- Ecosystem analysis
3.3.	Hematologic Malignancies Therapeutics Market dynamics
3.3.1.	Hematologic Malignancies Therapeutics? Market Forces
3.3.1.1.	Hematologic Malignancies Therapeutics Market driver analysis
3.3.1.2.	Hematologic Malignancies Therapeutics Market restraint/challenges analysis
3.3.1.3.	Hematologic Malignancies Therapeutics Market opportunity analysis
3.4.	Industry analysis - Porter's five force
3.4.1.	Bargaining power of supplier
3.4.2.	Bargaining power of buyer
3.4.3.	Threat of substitute
3.4.4.	Threat of new entrant
3.4.5.	Degree of competition
3.5.	Hematologic Malignancies Therapeutics Market PEST analysis, 2017
3.6.	Hematologic Malignancies Therapeutics Industry trends
3.7.	Competitive Ranking Analysis
4.	Hematologic Malignancies Therapeutics Market Size and Forecast by Type
4.1.	Key findings
4.2.	Leukemia
4.2.1.	Global market estimates and forecasts, 2017 ? 2025
4.2.1.1.	Acute Lymphocytic Leukemia
4.2.1.2.	Chronic Lymphocytic Leukemia
4.2.1.3.	Acute Myeloid Leukemia
4.2.1.4.	Chronic Myeloid Leukemia
4.2.2.	Lymphoma
4.2.2.1.	Global market estimates and forecasts, 2017 ? 2025
4.2.3.	Multiple Myeloma
4.2.3.1.	Global market estimates and forecasts, 2017 ? 2025
4.2.4.	Others
4.2.4.1.	Global market estimates and forecasts, 2017 ? 2025
5.	Hematologic Malignancies Therapeutics Market Size and Forecast by Therapy
5.1.	Key findings
5.2.	Chemotherapy
5.2.1.	Global market estimates and forecasts, 2017 ? 2025
5.3.	Radiotherapy
5.3.1.	Global market estimates and forecasts, 2017 ? 2025
5.4.	Immunotherapy
5.4.1.	Global market estimates and forecasts, 2017 ? 2025
5.5.	Stem Cell Transplantation
5.5.1.	Global market estimates and forecasts, 2017 ? 2025
5.6.	Others
5.6.1.	Global market estimates and forecasts, 2017 ? 2025
6.	Hematologic Malignancies Therapeutics Market Size and Forecast by Regions
6.1.	Key findings
6.2.	North America
6.2.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.2.3.	U.S.
6.2.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.2.4.	Canada
6.2.5.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.6.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.	Europe
6.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.3.	Germany
6.3.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.4.	UK
6.3.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.5.	France
6.3.5.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.5.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.6.	Italy
6.3.6.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.6.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.	Asia Pacific
6.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.3.	China
6.4.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.4.	India
6.4.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.5.	Japan
6.4.5.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.5.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.	Latin America
6.5.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.3.	Brazil
6.5.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.4.	Mexico
6.5.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.6.	Middle East & Africa
6.6.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.6.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
7.	Company Profiles
7.1.	Pfizer, Inc.
7.1.1.	Overview
7.1.2.	Financials
7.1.3.	Product Benchmarking
7.1.4.	Recent Developments
7.2.	Hoffmann-LA Roche ltd
7.2.1.	Overview
7.2.2.	Financials
7.2.3.	Product Benchmarking
7.2.4.	Recent Developments
7.3.	Sanofi-Aventis
7.3.1.	Overview
7.3.2.	Financials
7.3.3.	Product Benchmarking
7.3.4.	Recent Developments
7.4.	Bristol-Myers Squibb Company
7.4.1.	Overview
7.4.2.	Financials
7.4.3.	Product Benchmarking
7.4.4.	Recent Developments
7.5.	AbbVie, Inc.
7.5.1.	Overview
7.5.2.	Financials
7.5.3.	Product Benchmarking
7.5.4.	Recent Developments
7.6.	Novartis AG
7.6.1.	Overview
7.6.2.	Financials
7.6.3.	Product Benchmarking
7.6.4.	Recent Developments
7.7.	GlaxoSmithKline PLC
7.7.1.	Overview
7.7.2.	Financials
7.7.3.	Product Benchmarking
7.7.4.	Recent Developments
7.8.	Celgene Corporation
7.8.1.	Overview
7.8.2.	Financials
7.8.3.	Product Benchmarking
7.8.4.	Recent Developments
7.9.	Johnson & Johnson Services, Inc.
7.9.1.	Overview
7.9.2.	Financials
7.9.3.	Product Benchmarking
7.9.4.	Recent Developments
7.10.	Takeda Pharmaceutical Company limited
7.10.1.	Overview
7.10.2.	Financials
7.10.3.	Product Benchmarking
7.10.4.	Recent Developments


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Polaris Market Research

Vibration Monitoring Market Share, Size, Trends, Industry Analysis Report By Component (Hardware, Software, Services); By Monitoring Process (Online, Portable); By End-User (Automotive, Chemical, Aerospace and Defense, Food and Beverages, Construction, Mining, Oil and Gas, Others); By Regions: Market Size & Segment Forecast, 2019 - 2026

The global vibration monitoring market size is anticipated to reach USD 3,574.3 million by 2026 . The report 'Vibration Monitoring Market Analysis Report By Component (Hardware, Software, Services); By Monitoring Process (Online, Portable); By End-Us...

Used Cooking Oil (UCO) Market Share, Size, Trends, & Industry Analysis Report [By Source (Restaurants and Other Food Outlets, Household, Food Manufacturers, Caterers, Others) By Application (Biodiesel, Oleo Chemicals, Animal Feed, Others), By Regions]: Segment & Forecast, 2019 - 2026

The global used cooking oil (UCO) market size is anticipated to reach USD 773.5 Million by 2026, growing at a CAGR of 3.6% during the forecast period, according to a new research. The Report 'Used Cooking Oil Market Share, Size, Trends, & Industry An...

Refrigerant Market Share, Size, Trends, & Industry Analysis Report, [By Product (Inorganics, Fluorocarbons, Hydrocarbons), By Application (Domestic, Light Commercial, Commercial, Industrial, Air Conditioning, Heat Pumps) By Regions]: Segment Forecast, 2019 - 2026

The global refrigerants market size is anticipated to reach USD 22.16 billion by 2026 growing at a CAGR of 4.4% from 2019 to 2026 according to a new report. The report ?Refrigerant Market Share, Size, Trends, & Industry Analysis Report, [By Product ...

Pre-engineered Building Market Share, Size, Trends, & Industry Analysis Report [By Product (Steel Structure, Concrete Structure, Civil Structure, Others); By End-User (Residential, Commercial, Industrial, Infrastructure, Others) By Region]: Segment Forecast, 2019 - 2026

The global pre-engineered building market size is expected to reach USD 34.18 billion by 2026, growing at a CAGR of 13.9% during the forecast periods according to a new study. The Report ?Pre-engineered Building Market Share, Size, Trends, & Industry...

Glass Bonding Adhesives Market Share, Size, Trends, & Industry Analysis Report, [By Product (Polyurethane, Silicone, UV Curable Epoxy, UV Curable Cyanoacrylate, UV Epoxy Cyanoacrylate), By Application (Medical, Furniture, Electronics, Industrial Assembly, Automotive) By Regions]: Segment Forecast, 2018 - 2026

The global glass bonding adhesives market size estimated to be worth of USD 1.39 billion by 2026 and is projected to grow at a CAGR of 7.5 % over the forecast period. Glass bonding adhesives, are adhesives that are used to bond glass to glass or gl...

New Pharmaceuticals and Healthcare Reports